Review Reports
- Lei Ding1,2,†,
- Jiaqi Cao1,2,† and
- Wen Lin1,2,†
- et al.
Reviewer 1: Anonymous Reviewer 2: Aina He
Round 1
Reviewer 1 Report
The manuscript summaries and reviews a very important topic, the breast cancer research. It is a valuable reading.
Author Response
Response 1: Thank you very much for your recognition of our manuscript.
Reviewer 2 Report
Several dual CDK4/6 inhibitors have been approved by Federal Drug Administration (FDA) for the treatment of breast cancer. In this review, the authors summarized the roles of CDK in cell cycle and their therapeutic application breast cancer from the following aspects: 1. The molecular mechanical roles of CDKs in the cell cycle and transcription; 2. Dysregulation of CDKs in different breast cancer sub-types; 3. CDK inhibitors in breast cancer and clinical trials assessing CDK4/6 inhibitors for breast cancer; 4. Novel CDK inhibitors in breast cancer; 5. Combined treatment with CDK inhibitors and other agents in breast cancer. They reviewed the above topic basing on extensive up-to-date research/publications, giving the authors a intact overview of CDK from mechanism to clinical application. I recommend it published in IJMS.
Author Response
Response 1: Thank you very much for your recognition of our manuscript.